DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher – Should You Buy?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) shares shot up 0.6% on Friday . The company traded as high as $5.55 and last traded at $5.40. 110,887 shares changed hands during mid-day trading, an increase of 91% from the average session volume of 58,182 shares. The stock had previously closed at $5.37.

Analysts Set New Price Targets

DMAC has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and set a $6.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

DiaMedica Therapeutics Trading Up 0.6 %

The company has a market capitalization of $230.90 million, a P/E ratio of -9.64 and a beta of 1.51. The business’s fifty day moving average price is $4.51 and its 200 day moving average price is $3.76.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $185,000. Vanguard Group Inc. boosted its position in DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after buying an additional 211,351 shares during the last quarter. Magnolia Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at $87,000. Geode Capital Management LLC increased its stake in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after buying an additional 70,070 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics during the third quarter worth $40,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.